erhui1979 / iStockphoto.com
As CEO of the UK BioIndustry Association, Steve Bates works closely with industry and government and, by 2025, he wants the UK to become home to the third biggest global biotech cluster, as he explains to LSIPR.
From working as senior director at Genzyme to advising the UK government, Steve Bates has had a varied career, and he’s certainly no stranger to influencing public policy.
Since 2012, he’s settled into the role of CEO of the UK BioIndustry Association (BIA), a trade body founded more than 20 years ago at the infancy of biotechnology.
Bates has been involved in major BIA campaigns for improved access to finance, the extension of the UK Biomedical Catalyst (BMC), anti-microbial resistance and the opportunity the sector presents to long-term investors.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
Steve Bates, UK BioIndustry Association, BIA, industry, Brexit, UK biotech sector, LSIPR, BioIndustry, government
